United States

Cleveland Biolabs Inc (CBLI.OQ)

CBLI.OQ on NASDAQ Stock Exchange Capital Market

24 Mar 2017
Change (% chg)

$-0.01 (-0.65%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Cleveland Biolabs reports Q4 loss per share $0.11
Wednesday, 22 Feb 2017 04:15pm EST 

Cleveland Biolabs Inc : Cleveland Biolabs reports 2016 financial results and development progress . Q4 loss per share $0.11 . Q4 revenue $1.0 million versus $1.3 million .Cleveland Biolabs - as of Dec 31, cash, cash equivalents, short-term investments estimated to fund operations for at least one year beyond filing of form 10-k.  Full Article

Cleveland Biolabs quarterly loss per share $0.17
Monday, 15 Aug 2016 08:30am EDT 

Cleveland Biolabs Inc :Quarterly loss per share $0.17.  Full Article

Cleveland Biolabs posts a loss of $0.06 per share in Q1
Monday, 16 May 2016 07:30am EDT 

Cleveland Biolabs Inc : Cleveland Biolabs reports first quarter 2016 financial results and development progress . Q1 loss per share $0.06 .Q1 revenue $800,000 versus $600,000.  Full Article

Cleveland Biolabs and CFO Neil Lyons agreed on Lyon's termination of employment
Friday, 6 May 2016 05:55pm EDT 

Cleveland Biolabs Inc : Co, Neil Lyons, Co's CFO mutually agreed that Lyons would terminate his employment with company effective May 6, 2016 .Lyons to become a consultant; in his role as a consultant, Lyons will continue to serve as CFO of company.  Full Article

Department of Defense Awards Cleveland BioLabs $9.2 Million Contract for Advanced Development of Entolimod as Medical Radiation Countermeasure
Wednesday, 2 Sep 2015 11:49am EDT 

Cleveland BioLabs Inc:Department of Defense awards Cleveland Biolabs a $9.2 million contract for advanced development of entolimod as a medical radiation countermeasure.Dod contract will fund pivotal animal studies designed to support future submission of biologics license application for entolimod.Dod awarded co contract valued at up to $9.2 million to support further development of entolimod as a medical radiation countermeasure.Submitted application for pre-emergency use authorization to FDA in support of use of entolimod as medical radiation countermeasure.  Full Article

Cleveland BioLabs Inc announces new patents strengthening Entolimod portfolio
Tuesday, 18 Aug 2015 08:00am EDT 

Cleveland BioLabs Inc:Says allowance or issuance of several new patents for entolimod in U.S. and other countries, further bolstering its patent position.  Full Article

Cleveland BioLabs Inc announces date change for second quarter 2015 financial results
Friday, 31 Jul 2015 01:00pm EDT 

Cleveland BioLabs Inc:Says on August 12, 2015, it will report its financial results for the second quarter and six-month period ended June 30, 2015.  Full Article

Cleveland BioLabs, Inc announces results of phase 1 study of cblb612 in Russian federation
Monday, 13 Jul 2015 07:30am EDT 

Cleveland BioLabs, Inc:Announces results of phase 1 study of cblb612 in Russian federation.Says analysis of data showed cblb612 in doses ranging from 0.5 to 4 micrograms were generally well-tolerated.Administrations of cblb612 also resulted in rapid, dose-dependent increases of plasma levels of the specified cytokines.Says cytokine levels returned to baseline levels several hours after administration of the drug.Believe finding support phase 2 evaluation of cblb612 in clinical model of chemotherapy-induced myelosuppression;planning that study.  Full Article

Cleveland BioLabs enters into private placement agreement with strategic investor for $25 mln equity financing
Thursday, 25 Jun 2015 07:00am EDT 

Cleveland BioLabs Inc:Enters into securities purchase agreement with David Davidovich, a venture capital investor, for the sale of 6,459,948 unregistered common shares at price of $3.87 per share for an aggregate of $25 mln.The offering represents 35 pct premium to the closing market price of $2.86 on June 23, and 21 pct premium to the trailing 60-day volume weighted average price, as reported by Bloomberg.The parties expect to close the transaction on or about July 6.  Full Article

Cleveland BioLabs Inc submits pre-EUA dossier for entolimod to FDA
Monday, 15 Jun 2015 07:30am EDT 

Cleveland BioLabs Inc:Has submitted an application for pre-Emergency Use Authorization (pre-EUA) to U.S. Food and Drug Administration (FDA) in support of use of entolimod as a medical radiation countermeasure.Entolimod would be indicated for reducing the risk of death following exposure to potentially lethal irradiation occurring as the result of a radiation disaster.Pre-EUA is the regulatory path through which the FDA determines that certain unapproved medical products may be used in an emergency when there are no adequate, approved, and available alternatives.Products with pre-EUA status can be purchased by the US government for stockpiling in the event of a disaster. Achieving pre-EUA status in the United States can also support partnerships and foreign government interest in this program.  Full Article

More From Around the Web

BRIEF-Cleveland Biolabs reports Q4 loss per share $0.11

* Cleveland Biolabs reports 2016 financial results and development progress